Pages that link to "Q46334842"
Jump to navigation
Jump to search
The following pages link to Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations (Q46334842):
Displaying 50 items.
- Adenosine A 2A receptor antagonist istradefylline for levodopa-induced complications in Parkinson's disease (Q24201502) (← links)
- Available and emerging treatments for Parkinson's disease: a review (Q24633444) (← links)
- Adenosine receptors as drug targets--what are the challenges? (Q29346491) (← links)
- Adenosine A2A receptor signaling and golf assembly show a specific requirement for the gamma7 subtype in the striatum (Q30430643) (← links)
- Striatal adenosine A2A receptor expression is controlled by S-adenosyl-L-methionine-mediated methylation (Q34123200) (← links)
- Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg/day as augmentation for Parkinson's disease: a meta-analysis (Q34414817) (← links)
- International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update (Q34701303) (← links)
- Preclinical jockeying on the translational track of adenosine A2A receptors (Q34777609) (← links)
- Pathophysiological roles for purines: adenosine, caffeine and urate (Q35008049) (← links)
- Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. (Q35489240) (← links)
- Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. (Q35589979) (← links)
- Asian perspectives on the recognition and management of levodopa 'wearing-off' in Parkinson's disease (Q35781883) (← links)
- Adenosine A2A receptor in the monkey basal ganglia: ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum (Q35917127) (← links)
- Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A(2A) Antagonist in Cocaine Dependent Subjects (Q35990520) (← links)
- A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease (Q36057652) (← links)
- Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications (Q36251899) (← links)
- Reengineering the collision coupling and diffusion mode of the A2A-adenosine receptor: palmitoylation in helix 8 relieves confinement (Q36451989) (← links)
- Caffeine consumption and risk of dyskinesia in CALM-PD. (Q36717838) (← links)
- Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease (Q37348458) (← links)
- Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? (Q37506507) (← links)
- Management of Motor Complications in Parkinson Disease: Current and Emerging Therapies (Q37785174) (← links)
- Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. (Q37794467) (← links)
- Normal and abnormal functions of adenosine receptors in the central nervous system revealed by genetic knockout studies (Q37824017) (← links)
- Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists. (Q37844573) (← links)
- Priorities in Parkinson's disease research (Q37870670) (← links)
- The emergence of designed multiple ligands for neurodegenerative disorders (Q37871143) (← links)
- Milestones in Parkinson's disease therapeutics (Q37882596) (← links)
- Pharmacological and physiological characterization of the tremulous jaw movement model of parkinsonian tremor: potential insights into the pathophysiology of tremor (Q37902895) (← links)
- Wearing-off scales in Parkinson's disease: critique and recommendations (Q37903795) (← links)
- Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. (Q37924629) (← links)
- Future treatments for Parkinson's disease: surfing the PD pipeline (Q37950428) (← links)
- Istradefylline for the treatment of Parkinson's disease (Q37965615) (← links)
- New pharmacological avenues for the treatment of L-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors (Q37974709) (← links)
- Adenosine A2A antagonists in Parkinson's disease: what's next? (Q38010070) (← links)
- Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations (Q38103966) (← links)
- Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems (Q38123275) (← links)
- Non-dopaminergic treatments for motor control in Parkinson's disease (Q38126817) (← links)
- Therapeutic prospects for Parkinson disease (Q38137889) (← links)
- Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments (Q38156760) (← links)
- A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists. (Q38169996) (← links)
- Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions. (Q38170421) (← links)
- Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant (Q38199744) (← links)
- Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued (Q38200930) (← links)
- Advances in non-dopaminergic treatments for Parkinson's disease (Q38218083) (← links)
- Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials (Q38237288) (← links)
- ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome. (Q38242390) (← links)
- Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease (Q38262418) (← links)
- Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease (Q38284574) (← links)
- Dopamine heteroreceptor complexes as therapeutic targets in Parkinson's disease. (Q38285126) (← links)
- The safety of istradefylline for the treatment of Parkinson's disease (Q38353204) (← links)